Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.81 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | STAT1 | P42224 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946002 | 0.90 | EPHX2 (1.00) | EPHX2HPGDHTTALDH1A1TP53 | |
| SCHEMBL15871715 | 0.87 | EPHX2 (0.75) | EPHX2HPGDHTTALDH1A1TP53 | |
| SCHEMBL20458861 | 0.84 | EPHX2 (0.71) | EPHX2HPGDHTTALDH1A1TP53 | |
| SCHEMBL10268102 | 0.84 | EPHX2 (0.71) | EPHX2HPGDHTTALDH1A1TP53 | |
| SCHEMBL15623912 | 0.80 | EPHX2 (0.65) | EPHX2HPGDHTTALDH1A1TP53 | |
| SCHEMBL12305548 | 0.80 | HPGD (0.68) | EPHX2HPGDALOX15HTTALDH1A1 | |
| SCHEMBL133263 | 0.79 | NR1H4 (0.72) | EPHX2HTTNPC1RAB9ALMNA | |
| SCHEMBL3934244 | 0.78 | EPHX2 (1.00) | EPHX2HPGDHTTALDH1A1TP53 | |
| SCHEMBL29503806 | 0.77 | RAB9A (0.63) | EPHX2HPGDHTTALDH1A1TP53 | |
| SCHEMBL18193200 | 0.77 | EPHX2 (0.60) | EPHX2HPGDALDH1A1TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-06-05 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | PLIN1, PCK2, PLIN3 | EPHX2 3905/4885HPGD 710/4885ALOX15 701/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | EPHX2 4465/4885HPGD 2685/4885ALOX15 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.